

NTP Study Nominations

Dr. Scott Masten

NTP Board of Scientific Counselors Meeting

June 22, 2007



NTP Study Nomination Review Process

- Federal and State Agencies
- Public
- Labor Groups
- Academia
- Industry
- Advocacy and Other Organizations
- NIEHS/NTP

Study Nominations



NTP Office of Chemical Nomination and Selection



Federal Interagency review (ICCEC)



Public comment period

NTP develops draft research concepts



NTP Board of Scientific Counselors review (public meeting)



NTP Executive Committee review and selection



NTP designs and initiates studies based on resources and priorities

New Study Nominations

- 9 new study nominations reviewed by the ICCEC, December 2006
- Preliminary study recommendations developed for each nomination
- Public comment period, April-May 2007
- Review by the BSC, June 2007
 - Artificial butter flavoring and certain components (UFCW)
 - Asbestos, naturally occurring and atypical forms (NCEH/ATSDR and U.S. EPA)
 - Nanoscale silver (U.S. FDA)
 - o-Phthalaldehyde (NIOSH)
- Review by the BSC, December 2007 (anticipated)
 - Aminopyridines2-Methoxy-4-nitroaniline
 - Diethyl phthalateNanoscale gold
 - 2',2"-Dithiobisbenzanilide– Pentaethylenehexamine

Format for BSC Review

- NTP staff have prepared draft research concepts for the 4 nominations
 - Nomination background and rationale, significance, study approach, expected outcome
 - Proposed approach to address preliminary study recommendations for each nomination, not experimental study design
 - Outline issues and data gaps; hypotheses we could test
- Presentation of research concepts by NTP project leaders
- Comments from Board and ad hoc discussants
- Board discussion
- Public comments
- Board votes on whether nomination warrants study by the NTP

Charge Questions for the BSC

- Does the NTP research concept address the needs of the nomination?
- Is the proposed study approach as outlined in the research concept document appropriate in scope given the merit and priority of the nomination? Are there other studies that should be considered for this substance?
- Does the proposed research program address an important area of biomedical research (e.g. children's health, genetic susceptibility, specific environmental disease) and/or advance the field of environmental health sciences?
- Do the nomination and proposed research program merit NTP evaluation, and if so, what priority (low, moderate, high) should be given?



Questions and Comments